{'fraction_non_alphanumeric': 0.03023758099352052, 'fraction_numerical': 0.029157667386609073, 'mean_word_length': 5.28135593220339, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients.

OBJECTIVE
MicroRNAs have emerged as a new class of non-coding genes involved in regulating cell proliferation, differentiation and viability. Recent studies have identified miR-210 as one of a set of hypoxia-regulated microRNAs and demonstrated a direct regulatory role of HIF-1 alpha for its transcription. Here, we assessed miR-210 expression in Japanese triple-negative breast cancers and determined its clinical significance.


METHODS
TaqMan MicroRNA assays for miR-210 expression were performed on 161 samples of Japanese breast cancer tissue (58 triple-negative breast cancer and 103 estrogen receptor positive/HER2 negative). Correlations between miR-210 expression and clinicopathological factors were analyzed. The effects of several variables on survival were tested by a Cox proportional hazards regression analysis.


RESULTS
miR-210 expression in triple-negative breast cancers was significantly higher than in estrogen receptor-positive/HER2-negative breast cancers (P < 0.001). Patients whose triple-negative breast cancers showed low miR-210 expression experienced significantly better disease-free and overall survival than those with high miR-210 expression (P = 0.02 and P = 0.05, respectively). Although the prognosis of patients with triple-negative breast cancers is poor, Cox univariate and multivariate analyses demonstrated that a higher expression of miR-210 was an independent factor indicating a worse prognosis than for patients with a low level of miR-210.


CONCLUSIONS
The degree of miR-210 expression might be a clinically useful prognostic factor for decision-making regarding treatment in the adjuvant setting, especially in node-negative triple-negative breast cancer patients.